Efficacy and safety of bortezomib in patients with plasma cell leukemia

Abstract

A series of new cholesteric liquid‐crystalline polysiloxanes derived from steroid substituents were synthesized. The chemical structures of the monomers or polymers obtained were characterized by FTIR, element analyses, 1H NMR, and 13C NMR. Their mesogenic properties and thermal stability were investigated by differential scanning calorimetry, thermogravimetric analysis, polarizing optical microscopy, and X‐ray diffraction measurements. Monomers exhibited typical cholesteric focal‐conic or spiral texture. The polymers P1P6 showed cholesteric phase and P7 displayed smectic phase. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

“…No survival difference was observed between patients treated with bortezomib and those treated with old drugs, a result that does not confirm previous case reports. 7,8 This study is the largest series of patients with pPCL reported so far. It confirms the very poor prognosis specifically associated with pPCL.…”

Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

“…In a retrospective survey of unselected cases of both sPCL and pPCL (Musto et al, 2007), 12 patients received bortezomib for 1-6 cycles, as single agent or variously combined with other drugs. Three patients were treated with bortezomib as frontline therapy, nine after 1-4 lines of chemotherapy, including ASCT and thalidomide, with overall responses in 92% of the patients [five partial response (PR), four very good partial response (VGPR) and 2 CR].…”

Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen

“…Published response rates to bortezomib combination therapy in PPCL are promising. In the largest published series of PPCL patients treated with bortezomib, the median PFS and OS in patients with primary PCL had still not been reached at 21 months (the time of the report) [13].…”

“…There are a small number of reports on the utilization of bortezomib for PPCL [10][11][12][13][14][15][16][17][18][19][20]. Published response rates to bortezomib combination therapy in PPCL are promising.…”